Epizyme Stock Price, News & Analysis (NASDAQ:EPZM)

$13.25 0.60 (4.74 %)
(As of 12/14/2017 09:37 AM ET)
Previous Close$12.65
Today's Range$12.70 - $13.35
52-Week Range$9.30 - $20.45
Volume290,000 shs
Average Volume571,671 shs
Market Capitalization$876.42 million
P/E RatioN/A
Dividend YieldN/A
Beta2.01

About Epizyme (NASDAQ:EPZM)

Epizyme logoEpizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.

Receive EPZM News and Ratings via Email

Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EPZM
CUSIPN/A
Phone617-229-5872

Debt

Debt-to-Equity RatioN/A
Current Ratio13.69%
Quick Ratio13.69%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.01 million
Price / Sales114.60
Cash FlowN/A
Price / CashN/A
Book Value$3.48 per share
Price / Book3.81

Profitability

Trailing EPS($2.27)
Net Income$-110,210,000.00
Net MarginsN/A
Return on Equity-67.04%
Return on Assets-53.15%

Miscellaneous

Employees112
Outstanding Shares69,280,000

Epizyme (NASDAQ:EPZM) Frequently Asked Questions

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

How were Epizyme's earnings last quarter?

Epizyme, Inc. (NASDAQ:EPZM) issued its quarterly earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.65) by $0.02. View Epizyme's Earnings History.

When will Epizyme make its next earnings announcement?

Epizyme is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Epizyme.

Where is Epizyme's stock going? Where will Epizyme's stock price be in 2017?

10 brokers have issued 1 year price targets for Epizyme's stock. Their forecasts range from $16.00 to $26.00. On average, they expect Epizyme's share price to reach $23.00 in the next twelve months. View Analyst Ratings for Epizyme.

What are Wall Street analysts saying about Epizyme stock?

Here are some recent quotes from research analysts about Epizyme stock:

  • 1. Cann analysts commented, "Epizyme presented two posters at the American Society of Hematology Meeting on December 10-11, 2017. These included a biomarker study in non-Hodgkin’s lymphoma (NHL) and preliminary response data from the diffuse large B cell lymphoma (DLBCL) cohort from the ongoing phase II study of tazemetostat in NHL. The data presented is very supportive of our outlook." (12/12/2017)
  • 2. According to Zacks Investment Research, "Epizyme's efforts on developing its lead candidate, tazemetostat, for a number of hematological malignancies and genetically defined solid tumors are impressive. Additionally, its attempts to evaluate tazemetostat in combination with anti-PD 1 or PDL-1 agent are also encouraging. We believe, the company’s collaboration agreement with Celgene for small-molecule HMT inhibitors including pinometostat is a big positive. Epizyme’s share price has also outperformed the Zacks classified Medical/Biomedical Genetics industry year to date. However, with no approved product in its portfolio, Epizyme is highly dependent on its collaboration partners for top-line growth. Loss estimates have narrowed ahead of the Q3 earnings results. The company has a positive record of earnings surprises in recent quarters." (10/16/2017)
  • 3. Cowen Inc analysts commented, "Abstracts from ICML further support BGB-3111’s efficacy profile as being superior." (6/7/2017)

Who are some of Epizyme's key competitors?

Who are Epizyme's key executives?

Epizyme's management team includes the folowing people:

  • David M. Mott, Independent Chairman of the Board (Age 51)
  • Robert B. Bazemore Jr., President, Chief Executive Officer, Director (Age 49)
  • Susan E. Graf, Chief Business Officer, Principal Financial Officer (Age 44)
  • Matthew Ros, Chief Operating Officer (Age 50)
  • Peter T.C. Ho M.D. Ph.D., Executive Vice President, Chief Medical Officer (Age 55)
  • Suzanne Fleming, Senior Vice President - Finance, Principal Accounting Officer, Treasurer (Age 56)
  • Kevin T. Conroy, Director (Age 51)
  • Andrew R. Allen M.D. Ph.D., Independent Director (Age 50)
  • Kenneth M. Bate, Independent Director (Age 66)
  • Carl S. Goldfischer M.D., Independent Director (Age 58)

Who owns Epizyme stock?

Epizyme's stock is owned by many different of retail and institutional investors. Top institutional investors include NEA Management Company LLC (9.33%), Jennison Associates LLC (2.70%), Point72 Asset Management L.P. (1.33%), Schwab Charles Investment Management Inc. (0.31%), Bank of New York Mellon Corp (0.29%) and University of Notre Dame DU Lac (0.28%). Company insiders that own Epizyme stock include Andrew E Singer, Bay City Capital Fund V Co-Inv, David M Mott, Peter Tai-Ching Ho, Robert A Copeland and Robert J Gould. View Institutional Ownership Trends for Epizyme.

Who sold Epizyme stock? Who is selling Epizyme stock?

Epizyme's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC and California State Teachers Retirement System. Company insiders that have sold Epizyme company stock in the last year include Andrew E Singer, Peter Tai-Ching Ho and Robert A Copeland. View Insider Buying and Selling for Epizyme.

Who bought Epizyme stock? Who is buying Epizyme stock?

Epizyme's stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., NEA Management Company LLC, Schwab Charles Investment Management Inc., University of Notre Dame DU Lac, Dynamic Technology Lab Private Ltd, Macquarie Group Ltd., Swiss National Bank and Trexquant Investment LP. Company insiders that have bought Epizyme stock in the last two years include Bay City Capital Fund V Co-Inv, David M Mott and Peter Tai-Ching Ho. View Insider Buying and Selling for Epizyme.

How do I buy Epizyme stock?

Shares of Epizyme can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Epizyme's stock price today?

One share of Epizyme stock can currently be purchased for approximately $13.25.

How big of a company is Epizyme?

Epizyme has a market capitalization of $876.42 million and generates $8.01 million in revenue each year. The biopharmaceutical company earns $-110,210,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis. Epizyme employs 112 workers across the globe.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]


MarketBeat Community Rating for Epizyme (EPZM)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  272 (Vote Outperform)
Underperform Votes:  148 (Vote Underperform)
Total Votes:  420
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Epizyme (NASDAQ:EPZM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.922.923.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.00$23.00$24.11$24.10
Price Target Upside: 78.99% upside37.72% upside40.18% upside66.21% upside

Epizyme (NASDAQ:EPZM) Consensus Price Target History

Price Target History for Epizyme (NASDAQ:EPZM)

Epizyme (NASDAQ:EPZM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017OppenheimerSet Price TargetBuy$26.00MediumView Rating Details
12/12/2017CannReiterated RatingBuy$26.00MediumView Rating Details
11/2/2017HC WainwrightReiterated RatingBuy$25.00N/AView Rating Details
11/2/2017Leerink SwannReiterated RatingOutperform$28.00 -> $22.00N/AView Rating Details
11/2/2017Royal Bank of CanadaDowngradeOutperform -> Sector Perform$20.00 -> $16.00N/AView Rating Details
9/20/2017Jefferies GroupInitiated CoverageBuy -> Buy$23.00MediumView Rating Details
6/16/2017CitigroupBoost Price TargetBuy$20.00 -> $22.00LowView Rating Details
6/7/2017CowenReiterated RatingBuyHighView Rating Details
5/18/2017WedbushReiterated RatingOutperform$24.00HighView Rating Details
4/13/2017CIBCReiterated RatingOutperform -> OutperformLowView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
6/20/2016MizuhoReiterated RatingBuy$18.00N/AView Rating Details
12/22/2015SunTrust BanksInitiated CoverageBuy$21.00N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Epizyme (NASDAQ:EPZM) Earnings History and Estimates Chart

Earnings by Quarter for Epizyme (NASDAQ:EPZM)

Epizyme (NASDAQ EPZM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018($0.58)N/AView Earnings Details
11/1/2017Q3 2017($0.65)($0.63)$0.19 millionViewN/AView Earnings Details
8/4/2017Q2 2017($0.56)($0.48)$3.95 million$10.00 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.63)($0.56)$0.49 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.65)($0.60)$0.61 million$0.48 millionViewListenView Earnings Details
11/3/2016Q3($0.60)($0.42)$0.57 million$6.58 millionViewListenView Earnings Details
8/8/2016Q2($0.52)($0.49)$0.61 million$0.47 millionViewListenView Earnings Details
5/9/2016Q1($0.53)($0.41)$0.58 million$0.47 millionViewListenView Earnings Details
3/9/2016Q415($0.65)($0.53)$0.66 million$0.56 millionViewListenView Earnings Details
11/9/2015Q315($0.59)($0.56)$8.75 million$0.36 millionViewListenView Earnings Details
8/6/2015Q215($0.70)($0.63)$2.23 million$0.74 millionViewListenView Earnings Details
4/28/2015Q115($0.99)($1.75)$6.48 million$0.91 millionViewN/AView Earnings Details
3/12/2015Q414($0.54)($0.44)$10.10 million$10.35 millionViewListenView Earnings Details
11/6/2014Q314($0.54)($0.58)$7.00 million$8.20 millionViewN/AView Earnings Details
8/13/2014Q214($0.46)($0.40)$7.59 million$9.50 millionViewN/AView Earnings Details
5/13/2014Q114($0.48)($0.22)$7.67 million$13.39 millionViewN/AView Earnings Details
2/27/2014Q413($0.22)$0.52$9.00 million$36.32 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Epizyme (NASDAQ:EPZM) Earnings Estimates

2017 EPS Consensus Estimate: ($2.48)
2018 EPS Consensus Estimate: ($2.36)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.65)($0.63)($0.64)
Q2 20174($0.68)($0.41)($0.60)
Q3 20175($0.74)($0.57)($0.65)
Q4 20175($0.73)($0.54)($0.59)
Q1 20184($0.62)($0.54)($0.57)
Q2 20184($0.75)($0.55)($0.63)
Q3 20184($0.79)($0.54)($0.65)
Q4 20184($0.70)($0.23)($0.51)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Epizyme (NASDAQ:EPZM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Epizyme (NASDAQ EPZM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 25.20%
Institutional Ownership Percentage: 85.28%
Insider Trades by Quarter for Epizyme (NASDAQ:EPZM)
Insider Trades by Quarter for Epizyme (NASDAQ:EPZM)

Epizyme (NASDAQ EPZM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/24/2017Peter Tai-Ching HoInsiderSell15,000$16.44$246,600.00View SEC Filing  
9/25/2017Peter Tai-Ching HoInsiderSell15,000$16.81$252,150.00View SEC Filing  
9/18/2017David M MottDirectorBuy200,000$15.25$3,050,000.00View SEC Filing  
8/24/2017Peter Tai-Ching HoInsiderSell15,000$15.68$235,200.00View SEC Filing  
7/24/2017Peter Tai-Ching HoInsiderSell15,000$13.44$201,600.00View SEC Filing  
6/30/2017Andrew E SingerCFOSell3,024$15.50$46,872.00View SEC Filing  
6/26/2017Peter Tai-Ching HoInsiderSell15,000$14.87$223,050.00View SEC Filing  
6/6/2017Robert A CopelandInsiderSell2,500$13.45$33,625.00View SEC Filing  
5/25/2017Peter Tai-Ching HoInsiderSell15,000$16.11$241,650.00View SEC Filing  
5/2/2017Robert A CopelandInsiderSell5,000$17.44$87,200.00View SEC Filing  
4/4/2017Robert A CopelandInsiderSell5,000$16.36$81,800.00View SEC Filing  
3/31/2017Andrew E SingerCFOSell2,013$17.09$34,402.17View SEC Filing  
1/9/2017Andrew E SingerCFOSell1,013$12.04$12,196.52View SEC Filing  
12/9/2016Andrew E SingerCFOSell1,013$11.03$11,173.39View SEC Filing  
11/9/2016Andrew E SingerCFOSell1,013$10.40$10,535.20View SEC Filing  
10/10/2016Andrew E SingerCFOSell1,013$9.72$9,846.36View SEC Filing  
9/9/2016Andrew E SingerCFOSell1,013$7.55$7,648.15View SEC Filing  
8/9/2016Andrew E SingerCFOSell1,013$9.05$9,167.65View SEC Filing  
8/1/2016Robert A CopelandInsiderSell4,000$10.37$41,480.00View SEC Filing  
7/11/2016Andrew E SingerCFOSell1,013$10.36$10,494.68View SEC Filing  
7/5/2016Robert A CopelandInsiderSell4,000$10.03$40,120.00View SEC Filing  
6/9/2016Andrew E SingerCFOSell1,013$12.49$12,652.37View SEC Filing  
4/12/2016Andrew E SingerCFOSell1,013$12.42$12,581.46View SEC Filing  
3/9/2016Andrew E SingerCFOSell1,006$9.33$9,385.98View SEC Filing  
2/29/2016Peter Tai-Ching HoInsiderBuy636$7.47$4,750.92View SEC Filing  
2/10/2016Andrew E. SingerCFOSell12,158$9.54$115,987.32View SEC Filing  
1/12/2016Bay City Capital Fund V Co-InvMajor ShareholderBuy555,555$9.00$4,999,995.00View SEC Filing  
1/12/2016David M MottDirectorBuy1,111,111$9.00$9,999,999.00View SEC Filing  
1/4/2016Robert A. CopelandinsiderSell4,185$15.58$65,202.30View SEC Filing  
12/30/2015Robert J. GouldDirectorSell32,108$18.01$578,265.08View SEC Filing  
12/9/2015Peter Tai-Ching HoInsiderBuy1,000$14.69$14,690.00View SEC Filing  
12/7/2015Robert A. CopelandinsiderSell4,185$13.82$57,836.70View SEC Filing  
11/9/2015Robert A. CopelandinsiderSell4,185$16.26$68,048.10View SEC Filing  
10/5/2015Robert A. CopelandinsiderSell4,185$14.43$60,389.55View SEC Filing  
9/8/2015Robert A. CopelandinsiderSell4,185$19.58$81,942.30View SEC Filing  
9/8/2015Robert J. GouldCEOSell60,000$19.86$1,191,600.00View SEC Filing  
7/6/2015Robert A CopelandInsiderSell8,371$22.86$191,361.06View SEC Filing  
7/6/2015Robert J GouldCEOSell60,000$23.22$1,393,200.00View SEC Filing  
5/5/2015Peter Tai-Ching HoInsiderBuy800$16.36$13,088.00View SEC Filing  
12/2/2014Peter Tai-Ching HoInsiderBuy1,000$21.17$21,170.00View SEC Filing  
11/17/2014Robert A CopelandEVPSell20,000$22.68$453,600.00View SEC Filing  
11/3/2014Robert A CopelandEVPSell20,000$25.47$509,400.00View SEC Filing  
11/3/2014Robert J GouldCEOSell30,000$24.95$748,500.00View SEC Filing  
10/7/2014Robert A CopelandEVPSell20,000$26.90$538,000.00View SEC Filing  
10/1/2014Robert J GouldCEOSell30,000$26.28$788,400.00View SEC Filing  
10/1/2014Stephen GarbaczInsiderSell868$27.06$23,488.08View SEC Filing  
9/22/2014Robert A CopelandEVPSell20,000$25.55$511,000.00View SEC Filing  
9/15/2014Eric HedrickInsiderSell2,000$28.67$57,340.00View SEC Filing  
9/4/2014Carl GoldfischerDirectorSell4,000$35.14$140,560.00View SEC Filing  
8/26/2014Bay City Capital LlcMajor ShareholderSell200,000$35.14$7,028,000.00View SEC Filing  
8/25/2014Bay City Capital LlcMajor ShareholderSell366,666$33.98$12,459,310.68View SEC Filing  
8/18/2014Robert A CopelandEVPSell10,830$36.07$390,638.10View SEC Filing  
8/15/2014Ryan D DrantMajor ShareholderSell4,061$36.54$148,388.94View SEC Filing  
8/4/2014Jason P RhodesCFOSell30,000$29.74$892,200.00View SEC Filing  
8/4/2014Robert A CopelandEVPSell20,000$29.42$588,400.00View SEC Filing  
7/15/2014Eric HedrickInsiderSell2,000$31.35$62,700.00View SEC Filing  
7/7/2014Jason P RhodesCFOSell30,000$32.74$982,200.00View SEC Filing  
7/1/2014Robert J GouldCEOSell30,000$31.53$945,900.00View SEC Filing  
6/23/2014Robert A CopelandEVPSell20,000$28.42$568,400.00View SEC Filing  
6/16/2014Eric HedrickInsiderSell2,000$26.42$52,840.00View SEC Filing  
6/16/2014Robert A CopelandEVPSell25,012$26.38$659,816.56View SEC Filing  
6/2/2014Robert J GouldCEOSell30,000$22.20$666,000.00View SEC Filing  
5/19/2014Robert CopelandEVPSell5,000$22.28$111,400.00View SEC Filing  
5/5/2014Jason RhodesCFOSell30,000$21.53$645,900.00View SEC Filing  
5/5/2014Robert CopelandEVPSell10,000$21.29$212,900.00View SEC Filing  
5/1/2014Robert GouldCEOSell30,000$21.91$657,300.00View SEC Filing  
4/28/2014Robert CopelandEVPSell13,800$20.73$286,074.00View SEC Filing  
4/7/2014Jason RhodesCFOSell25,000$20.05$501,250.00View SEC Filing  
4/7/2014Robert GouldCEOSell30,000$20.22$606,600.00View SEC Filing  
2/10/2014Celgene European Investment Comajor shareholderBuy340,000$29.25$9,945,000.00View SEC Filing  
1/6/2014Jason RhodesCFOSell10,000$20.19$201,900.00View SEC Filing  
12/16/2013Robert CopelandEVPSell4,600$21.21$97,566.00View SEC Filing  
12/2/2013Robert CopelandEVPSell5,000$20.70$103,500.00View SEC Filing  
11/15/2013M James Barrettmajor shareholderBuy406,500$19.68$7,999,920.00View SEC Filing  
6/5/2013David M MottDirectorBuy400,000$15.00$6,000,000.00View SEC Filing  
6/5/2013Venture Fund I L.P. AstellasMajor ShareholderBuy15,333$15.00$229,995.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Epizyme (NASDAQ EPZM) News Headlines

Source:
DateHeadline
Pre-Market Technical Scan on Biotech Equities -- BioMarin Pharma, Aptevo Therapeutics, Otonomy, and Epizyme - PR Newswire (press release)Pre-Market Technical Scan on Biotech Equities -- BioMarin Pharma, Aptevo Therapeutics, Otonomy, and Epizyme - PR Newswire (press release)
www.prnewswire.com - December 12 at 10:01 AM
Epizyme (EPZM) Highlights Preclinical Data on Novel G9a Program ... - StreetInsider.comEpizyme (EPZM) Highlights Preclinical Data on Novel G9a Program ... - StreetInsider.com
www.streetinsider.com - December 11 at 5:27 PM
Epizyme (EPZM) Presents New Biomarker Data on Tazemetostat at ASH - StreetInsider.comEpizyme (EPZM) Presents New Biomarker Data on Tazemetostat at ASH - StreetInsider.com
www.streetinsider.com - December 11 at 5:27 PM
Comparing Epizyme (EPZM) and Nantkwest (NK)Comparing Epizyme (EPZM) and Nantkwest (NK)
www.americanbankingnews.com - December 11 at 3:34 PM
EZM8266 is the First of Three New Compounds to be Named as Part of Epizyme’s Vision 2020EZM8266 is the First of Three New Compounds to be Named as Part of Epizyme’s Vision 2020
globenewswire.com - December 11 at 10:19 AM
Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of Hematology Annual MeetingEpizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of Hematology Annual Meeting
finance.yahoo.com - December 11 at 10:19 AM
Epizyme, Inc. (EPZM) Receives Average Recommendation of "Buy" from BrokeragesEpizyme, Inc. (EPZM) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 1 at 6:13 AM
Epizyme to Present at the Jefferies 2017 London Healthcare ConferenceEpizyme to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 10 at 1:09 PM
FY2017 EPS Estimates for Epizyme, Inc. Increased by Analyst (EPZM)FY2017 EPS Estimates for Epizyme, Inc. Increased by Analyst (EPZM)
www.americanbankingnews.com - November 6 at 5:50 AM
Brokers Offer Predictions for Epizyme, Inc.s FY2017 Earnings (EPZM)Brokers Offer Predictions for Epizyme, Inc.'s FY2017 Earnings (EPZM)
www.americanbankingnews.com - November 6 at 5:50 AM
Brokers Issue Forecasts for Epizyme, Inc.s FY2017 Earnings (EPZM)Brokers Issue Forecasts for Epizyme, Inc.'s FY2017 Earnings (EPZM)
www.americanbankingnews.com - November 6 at 5:50 AM
Epizyme, Inc. (EPZM) Receives Consensus Recommendation of "Buy" from BrokeragesEpizyme, Inc. (EPZM) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 6 at 3:46 AM
Epizyme Enters Oversold Territory (EPZM)Epizyme Enters Oversold Territory (EPZM)
www.thestreet.com - November 3 at 1:01 PM
Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3 - NasdaqEpizyme (EPZM) Reports Narrower-than-Expected Loss in Q3 - Nasdaq
www.nasdaq.com - November 2 at 7:29 PM
Epizymes (EPZM) Outperform Rating Reaffirmed at Leerink SwannEpizyme's (EPZM) Outperform Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - November 2 at 11:03 AM
Edited Transcript of EPZM earnings conference call or presentation 1-Nov-17 8:30pm GMTEdited Transcript of EPZM earnings conference call or presentation 1-Nov-17 8:30pm GMT
finance.yahoo.com - November 2 at 5:31 AM
Epizyme Reports Third Quarter 2017 Operating Results and Company Updates - GlobeNewswire (press release)Epizyme Reports Third Quarter 2017 Operating Results and Company Updates - GlobeNewswire (press release)
globenewswire.com - November 1 at 7:26 PM
Epizyme Reports Third Quarter 2017 Operating Results and Company UpdatesEpizyme Reports Third Quarter 2017 Operating Results and Company Updates
finance.yahoo.com - November 1 at 7:26 PM
Epizyme reports 3Q lossEpizyme reports 3Q loss
finance.yahoo.com - November 1 at 7:26 PM
Epizyme, Inc. (EPZM) Releases Quarterly  Earnings Results, Beats Expectations By $0.02 EPSEpizyme, Inc. (EPZM) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - November 1 at 5:28 PM
$3.67 Million in Sales Expected for Epizyme, Inc. (EPZM) This Quarter$3.67 Million in Sales Expected for Epizyme, Inc. (EPZM) This Quarter
www.americanbankingnews.com - October 31 at 2:50 AM
Epizyme (EPZM) and The Competition Head to Head AnalysisEpizyme (EPZM) and The Competition Head to Head Analysis
www.americanbankingnews.com - October 30 at 7:40 PM
Your Daily Pharma Scoop: Gileads Unappreciated Opportunity, Mercks Keytruda Stumble, Epizymes Positive ResultsYour Daily Pharma Scoop: Gilead's Unappreciated Opportunity, Merck's Keytruda Stumble, Epizyme's Positive Results
seekingalpha.com - October 30 at 7:06 PM
ETFs with exposure to Epizyme, Inc. : October 30, 2017ETFs with exposure to Epizyme, Inc. : October 30, 2017
finance.yahoo.com - October 30 at 7:06 PM
Epizyme (EPZM) vs. Aldeyra Therapeutics (ALDX) Financial SurveyEpizyme (EPZM) vs. Aldeyra Therapeutics (ALDX) Financial Survey
www.americanbankingnews.com - October 28 at 1:30 PM
Epizyme Presents Data from a Phase 1 Trial of Tazemetostat in Children with Relapsed or RefractoryEpizyme Presents Data from a Phase 1 Trial of Tazemetostat in Children with Relapsed or Refractory
www.nasdaq.com - October 28 at 1:34 AM
Epizyme (EPZM) Presents Data from Phase 1 Trial of Tazemetostat in Children with Relapsed or Refractory INI1-Negative Solid Tumors at AACR-NCI-EORTCEpizyme (EPZM) Presents Data from Phase 1 Trial of Tazemetostat in Children with Relapsed or Refractory INI1-Negative Solid Tumors at AACR-NCI-EORTC
www.streetinsider.com - October 28 at 1:34 AM
Epizyme Presents Data from a Phase 1 Trial of Tazemetostat in Children with Relapsed or Refractory INI1-Negative Solid Tumors at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsEpizyme Presents Data from a Phase 1 Trial of Tazemetostat in Children with Relapsed or Refractory INI1-Negative Solid Tumors at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
finance.yahoo.com - October 28 at 1:34 AM
Epizyme (EPZM) Presents Data from Phase 1 Trial of Tazemetostat ... - StreetInsider.comEpizyme (EPZM) Presents Data from Phase 1 Trial of Tazemetostat ... - StreetInsider.com
www.streetinsider.com - October 27 at 3:30 PM
Epizyme Announces Date of Third Quarter 2017 Financial Results - GlobeNewswire (press release)Epizyme Announces Date of Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - October 25 at 8:09 PM
Peter Tai-Ching Ho Sells 15,000 Shares of Epizyme, Inc. (EPZM) StockPeter Tai-Ching Ho Sells 15,000 Shares of Epizyme, Inc. (EPZM) Stock
www.americanbankingnews.com - October 25 at 2:39 PM
Epizyme, Inc. (EPZM) Set to Announce Earnings on WednesdayEpizyme, Inc. (EPZM) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - October 25 at 9:48 AM
Contrasting Forward Pharma A/S (FWP) & Epizyme (EPZM)Contrasting Forward Pharma A/S (FWP) & Epizyme (EPZM)
www.americanbankingnews.com - October 19 at 9:06 AM
ETFs with exposure to Epizyme, Inc. : October 17, 2017ETFs with exposure to Epizyme, Inc. : October 17, 2017
finance.yahoo.com - October 17 at 3:31 PM
Epizyme, Inc. (EPZM) Given Consensus Rating of "Buy" by BrokeragesEpizyme, Inc. (EPZM) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 12 at 5:06 AM
Todays Research Report Coverage on Biotech Stocks -- Epizyme, FibroGen, Global Blood Therapeutics, and Intercept PharmaToday's Research Report Coverage on Biotech Stocks -- Epizyme, FibroGen, Global Blood Therapeutics, and Intercept Pharma
www.bizjournals.com - October 11 at 7:55 PM
-$0.65 Earnings Per Share Expected for Epizyme, Inc. (EPZM) This Quarter-$0.65 Earnings Per Share Expected for Epizyme, Inc. (EPZM) This Quarter
www.americanbankingnews.com - October 10 at 6:28 PM
ETFs with exposure to Epizyme, Inc. : October 6, 2017ETFs with exposure to Epizyme, Inc. : October 6, 2017
finance.yahoo.com - October 6 at 6:44 PM
Epizyme, Inc. :EPZM-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017Epizyme, Inc. :EPZM-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017
finance.yahoo.com - October 5 at 5:31 PM
Insider Selling: Epizyme, Inc. (EPZM) Insider Sells 15,000 Shares of StockInsider Selling: Epizyme, Inc. (EPZM) Insider Sells 15,000 Shares of Stock
www.americanbankingnews.com - September 26 at 7:44 PM
 Brokerages Expect Epizyme, Inc. (EPZM) Will Announce Quarterly Sales of $3.67 Million Brokerages Expect Epizyme, Inc. (EPZM) Will Announce Quarterly Sales of $3.67 Million
www.americanbankingnews.com - September 24 at 10:04 AM
Epizyme, Inc. (EPZM) Coverage Initiated by Analysts at Jefferies Group LLCEpizyme, Inc. (EPZM) Coverage Initiated by Analysts at Jefferies Group LLC
www.americanbankingnews.com - September 23 at 9:38 PM
Epizyme, Inc. Expected to Earn Q3 2017 Earnings of ($0.57) Per Share (EPZM)Epizyme, Inc. Expected to Earn Q3 2017 Earnings of ($0.57) Per Share (EPZM)
www.americanbankingnews.com - September 22 at 6:38 AM
-$0.66 Earnings Per Share Expected for Epizyme, Inc. (EPZM) This Quarter-$0.66 Earnings Per Share Expected for Epizyme, Inc. (EPZM) This Quarter
www.americanbankingnews.com - September 22 at 2:16 AM
Epizyme, Inc. (EPZM) Forecasted to Post FY2017 Earnings of ($2.54) Per ShareEpizyme, Inc. (EPZM) Forecasted to Post FY2017 Earnings of ($2.54) Per Share
www.americanbankingnews.com - September 21 at 9:00 AM
Epizyme (EPZM) Looks Good: Stock Adds 7.8% in SessionEpizyme (EPZM) Looks Good: Stock Adds 7.8% in Session
finance.yahoo.com - September 20 at 7:14 PM
FY2020 Earnings Estimate for Epizyme, Inc. (EPZM) Issued By Oppenheimer HoldingsFY2020 Earnings Estimate for Epizyme, Inc. (EPZM) Issued By Oppenheimer Holdings
www.americanbankingnews.com - September 20 at 1:56 PM
Epizyme Announces Closing of Public Offering of Common Stock - GlobeNewswire (press release)Epizyme Announces Closing of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - September 20 at 4:21 AM
Epizyme Announces Closing of Public Offering of Common StockEpizyme Announces Closing of Public Offering of Common Stock
finance.yahoo.com - September 19 at 6:18 PM
Oppenheimer Holdings, Inc. Reiterates "Buy" Rating for Epizyme, Inc. (EPZM)Oppenheimer Holdings, Inc. Reiterates "Buy" Rating for Epizyme, Inc. (EPZM)
www.americanbankingnews.com - September 19 at 3:52 PM

SEC Filings

Epizyme (NASDAQ:EPZM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Epizyme (NASDAQ:EPZM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Epizyme (NASDAQ EPZM) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.